Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden Show more
Location: Luntmakargatan 46, Stockholm, 111 37, Sweden | Website: https://www.oncopeptides.com/sv | Industry: Biotechnology | Sector: Healthcare
Market Cap
55.98M
52 Wk Range
$0.27 - $0.27
Previous Close
$0.26
Open
$0.26
Volume
N/A
Day Range
$0.26 - $0.26
Enterprise Value
20.2M
Cash
178.5M
Avg Qtr Burn
-65.14M
Insider Ownership
34.49%
Institutional Own.
60.99%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pepaxto (Melflufen) Details Multiple myeloma | Phase 3 Update |